T he mammalian target of rapamycin (mTOR) is a serinethreonine kinase that as part of the mTOR complex 1 (mTORC1) regulates anabolic and catabolic processes required for autophagy, RNA translation, protein synthesis, ribosome biogenesis, and cell survival.
liver-specific Tsc1-knockout (Li-Tsc1
KO
) and Raptor-knockout (Li-Rap KO ) mice, we showed that the mechanism of increased LDL involved mTOR-mediated suppression of Pcsk9 mRNA resulting in the upregulation of LDLR protein. 9 Paradoxically, the mTORC1 inhibitor, rapamycin, was reported to reduce inflammation and atherosclerosis despite increasing plasma LDL levels. 8 Because LDL levels are usually a dominant factor in atherogenesis, this suggested a potent antiatherogenic effect of mTORC1 inhibition independent of plasma LDL levels. Inflammation has an important role in atherosclerosis, 11 raising the possibility that rapamycin is working through an anti-inflammatory mechanism.
In view of the central role of macrophages in atherosclerotic inflammation, we tested this hypothesis by crossing Tsc1 flox/flox and Rap flox/flox mice with LysM-Cre mice, resulting in increased and decreased mTORC1 activity in macrophages, respectively, and then transplanted the bone marrow (BM) of these mice into Ldlr −/− recipients followed by Western-type diet (WTD) feeding to induce atherogenesis. Although studies with the Mac-Tsc1 KO mice were limited by premature death, the Mac-Rap KO BM-transplanted Ldlr −/− mice displayed reduced macrophage content in atherosclerotic lesions. This seemed to be related to decreased macrophage expression of proatherogenic chemokines. Additional mechanistic studies revealed that when macrophages were treated with minimally modified LDL (mmLDL), mTORC1 activity amplified the induction of chemokines by increasing interleukin 6 (IL6) signaling.
Methods
An expanded Methods section is available in the Online Data Supplement. flox/flox mice backcrossed to C57BL/6J for 9 generations were kindly provided by Dr Kwiatkowski. Ldlr −/− mice (stock number 002207) were purchased from Jackson Laboratory. Mice were fed a WTD (21% milk fat, 0.2% cholesterol; Harlan Teklad; TD88137) or chow diet (Purina Mills; diet 5053). All protocols were approved by the Institutional Animal Care and Use Committee of Columbia University.
Animals and Diet

Results
Atherosclerosis Is Decreased in BM-Transplanted
Mac-Rap KO 
Ldlr −/− Mice
In a preliminary study, we found that phospho-S6 ribosomal protein (phosphoS6), a downstream target of mTORC1, was increased in peritoneal macrophages from Ldlr −/− mice fed an atherogenic WTD compared with chow (Online Figure IA) , and also from chow-fed ob/ob mice compared with wild-type mice (data not shown). To investigate the role of mTORC1 in macrophages, we crossed Rap flox/flox with LysM-Cre mice, which are known to delete targets in macrophages and neutrophils and, to a lesser extent, in monocytes and myeloid progenitors. 12 For simplicity, we refer to these mice as Mac-Rap KO mice, while recognizing that the knockout is not completely macrophage-specific. In addition, we performed select studies in Mac-Tsc1 KO mice; because TSC1 is an upstream inhibitor of mTORC1, these mice have increased mTORC1 activity. However, because of premature mortality at ≈4 months of age, we were not able to carry out atherosclerosis studies in these mice. Figure IB) . Five weeks after BM transplantation, reconstitution of the BM was >90% (Online Figure  IC) . Body weights, spleen weights, triglyceride levels, and cholesterol levels were similar in the 2 groups ( Figure 1A ; Online Figure ID ). There was no difference in lipoprotein cholesterol distribution ( Figure 1B) . Ldlr −/− mice transplanted with BM from Rap flox/flox or Mac-Rap KO had similar levels of neutrophils, monocytes, and Ly6C hi monocytes in peripheral blood after 10 weeks of WTD feeding (Online Figure IF) . In contrast, the percentages of Ly6C -WT mice at the 10-week time point (Online Figure IG) . After 10 weeks of WTD feeding, mice were euthanized, and atherogenesis was assessed in the aortic root. In Ldlr −/− mice, macrophage deficiency of Raptor decreased atherosclerotic lesion area by 25% compared with the Ldlr −/− -WT control group ( Figure 1C and 1D) . To analyze the lesion phenotype further, we examined lesion composition. Morphological analyses of the cross-sectional lesions showed no significant difference in collagen content (Online Figure IIA) . In contrast, the analysis of macrophage and cholesterol ester content uncovered significant reductions in mac-3 + immunostaining and oil red O staining in Mac-Rap KO BM-transplanted Ldlr −/− mice ( Figure 1E ; Online Figure IIC) . The smooth muscle cell and T-cell contents remained unchanged between groups as assessed by immunostaining with α-actin and CD3 antibodies, respectively (Online Figure IIB Ki67-positive and terminal deoxynucleotidyl transferase dUTP nick-end labeling-positive macrophage staining were similar between the groups, suggesting no difference in local proliferation or apoptosis of macrophages, respectively. In addition, because reduced mTORC1 activity might lead to increased macrophage autophagy, which could contribute to decreased atherosclerosis, we stained lesions for P62, an autophagy marker. There was a 50% decrease in P62 expression, indicative of moderately increased autophagy (Online Figure  IIIA and IIIB). However, Razani et al 15 showed that a 3.5-fold increase of P62 in Beclin-Het autophagy-deficient mice was insufficient to change atherosclerosis, whereas 7-to 9-fold increases were associated with moderately increased lesion formation. This suggests that small changes in autophagy as we observed here might not affect atherogenesis.
To address potential antiatherogenic mechanisms in MacRap KO BM-transplanted mice further, we performed laser capture microscopy in lesions and assessed the mRNA expression of proatherogenic chemokines and cytokines in macrophage-rich areas. Interestingly, this showed markedly decreased mRNA expression of chemokines Ccl2/Mcp-1, Ccl3/Mip1α, Ccl6, and Cxcl2 in Ldlr −/− -Mac-Rap KO mice compared with control, whereas there were no significant differences in Il10, Tnfα, Il12p40, and Il6 mRNA levels between the 2 groups ( Figure 1F ). All of the upregulated chemokines are involved in monocyte recruitment and have been reported to accelerate atherogenesis. [16] [17] [18] Consistent with these findings, the level of chemokine (C-C motif) ligand 2 (CCL2) in plasma was decreased to 32% of controls in Ldlr Figure   IE ). These results suggested that the attenuation of development of atherosclerosis in Mac-Rap KO BM-transplanted mice was at least partly because of decreased macrophage chemokine production, leading to reduced monocyte recruitment into lesions.
To assess monocyte recruitment, we performed adoptive transfer experiments using classical (Ly6C 
Chemokine Expression Induced by mmLDL Is Regulated by mTORC1
Oxidation or other modifications of LDL are thought to have an important role in atherogenesis.
19 mmLDL prepared by (Figure 2A) . However, the expression of Ccl2, Ccl3, Ccl6, Ccl7, and Cxcl2 was reduced by 48%, 41%, 61%, 63%, and 63%, respectively, compared with floxed controls ( Figure 2B ). An additional control group consisting of macrophages from LysM-Cre mice showed no difference in responses compared with Rap flox/ flox controls. Consistent with these findings, CCL2 levels in the cell culture media were decreased by 50% ( Figure 2C ).
The findings in Mac-Rap KO mice suggested that the anti-inflammatory effects of mTORC1 inhibition may be mediated via repression of chemokine production. To further test this hypothesis, we isolated BMDM from Mac-Tsc1 KO and Tsc1 flox/flox mice and measured gene expression. mmLDL increased the levels of chemokine expression in macrophages of both genotypes, but the effects were significantly more pronounced for Mac-Tsc1 KO than for control macrophages (Online Figure IVA) . Although there were trends toward higher levels of induced Tnfα and Il6 mRNAs in the Mac-Tsc1 KO mice (Online Figure IVB) , these effects were less pronounced than for the chemokine genes. As expected, rapamycin treatment reversed these effects, but not for Tnfα and Il6 (Online Figure IVA and IVB) .
Mechanism of Regulation of Chemokine Expression by mTORC1
To examine the mechanisms mediating the modification of chemokine expression by mTORC1 further, we explored whether the transcriptional repressor B-cell lymphoma 6 (BCL6), which has a key role in regulating macrophage chemokine expression, was involved. [21] [22] [23] [24] Barish et al 22 used macrophages from Bcl6-knockout mice and showed that BCL6-containing promoter complexes constrained inflammatory cytokine and chemokine responses to mmLDL. However, the BCL6 protein and mRNA expression were not changed by macrophage Raptor deficiency ( Figure 3A and 3C) . Interestingly, the sequence of BCL6 consensus binding site overlaps that of signal transducer and activator of transcription (STAT) factor-binding sites, 24, 25 and competition between BCL6 and STATs likely modulates innate immunologic functions. 24 STAT3 is phosphorylated by Janus kinase tyrosine kinases at Tyr705, which transduces the signals of IL6. However, STAT3 also requires phosphorylation on Ser727 to achieve maximal transcriptional activity via the formation of stable STAT3-STAT3-DNA complexes. 26, 27 Several reports suggested that mTORC1 is responsible for STAT3 serine phosphorylation. 28 Figure 3A and 3B). In contrast, the phosphorylation of STAT3 at Tyr705 was similar in the 2 groups ( Figure 3A and 3B) . As shown by immunofluorescence confocal microscopy, nuclear phospho-STAT3Ser727 were measured by quantitative polymerase chain reaction and normalized to expression levels observed without treatment (Ctrl). B, Ccl2, Ccl3, Ccl6, Ccl7, and Cxcl2 gene expression in BMDMs of LysM-Cre, Rf/f, and Rf/fCre mice after 2 h of mmLDL (50 μg/mL) treatment; n=3; *P<0.05. C, BMDMs were treated with mmLDL for 2 h, washed with PBS, and then incubated with fresh media for another 18 h. Chemokine (C-C motif) ligand 2 (CCL2) in the media was measured by ELISA, and values were normalized to total cellular protein; n=3; *P<0.05. N.S. indicates not significant. staining was increased by mmLDL, and this was reduced by Raptor deficiency (Online Figure V) , which is consistent with that of lesional macrophages ( Figure 3C and 3D) .
Opposite to Mac-Rap KO macrophages, the phosphorylation of S6 induced by mmLDL was increased by 2.3-fold in Mac-Tsc1 KO Figure VIA and VIB) . Moreover, the phosphorylation of STAT3 at Ser727 was induced 2.2-fold in Tsc1-knockout BMDM compared with the Tsc1 flox/flox group, whereas Tyr705 was not influenced (Online Figure VIA and VIB). Preincubation with rapamycin reversed the induction of both phosphoS6 and phospho-STAT3Ser727 (Online Figure VIA and VIB) . However, the phosphorylation of STAT3 at Tyr705 was not influenced by TSC1 deficiency or rapamycin treatment (Online Figure VIA and VIB) .
BMDM compared with controls (Online
mTOR Activation Enhances the Competition Between STAT3 and BCL6 on the Ccl2 Promoter
To investigate the underlying mechanism of the regulation of chemokines by mTORC1 further, we cotransfected a Bcl6 expression plasmid and Ccl2 promoter-reporter plasmid into HEK-293T cells. Compared with the empty vehicle transfection control, the luciferase activity was reduced by Bcl6 transfection. Cotransfection of wild-type STAT3 (CA-STAT3) reversed the reduction of Bcl6, whereas neither dominant-negative (DN-STAT3) nor Ser727-mutated versions of STAT3 (STAT3A) had any effect on the decreased luciferase activity caused by Bcl6 ( Figure 4A ). This suggests that phosphorylation of Ser727, as mediated by mTORC1, is essential for the ability of STAT3 to reverse the inhibitory effect of BCL6 on the chemokine promoter. We next cotransfected RAW264.7 macrophages with the Ccl2 promoter plasmid and either control or Bcl6 plasmid. Luciferase activity induced by IL6 was partly reversed by Bcl6 expression (Online Figure  VIIA) . Notably, quantitative chromatin immunoprecipitation assays showed impaired enrichment of STAT3 protein at the Ccl2 promoter in Mac-Rap KO BMDM compared with control BMDM in response to mmLDL treatment ( Figure 4B) . Cyclin D2 and Gapdh were performed as positive and negative control, respectively (Online Figure VIIB) . Together, these experiments suggest that the phosphorylation of Ser727 of STAT3 enhances its ability to counteract the effect of BCL6 at the Ccl2 promoter.
Role of mTORC1 and IL6 in the Induction of Chemokine Gene Expression by mmLDL
STAT3 plays a critical role in the IL6 signaling pathway. To confirm the role of mTORC1/STAT3 and investigate the effect of IL6 in mmLDL-induced chemokine production further, we used IL6 and its neutralizing antibody. When macrophages were incubated with mmLDL in the presence of the IL6 neutralizing antibody, there was no induction of chemokine gene expression, indicating a key role of mmLDL-induced IL6 expression in chemokine production ( Figure 5A ; Online Figure VIIIA) . Next, we asked whether the effects of IL6 on chemokine gene expression could be influenced by mTORC1 Because chemokines produced by macrophages in lesions are thought to promote monocyte/macrophage recruitment to lesions, we assessed the function of our findings on chemokine expression in a macrophage migration assay. In response to mmLDL treatment, 1.6-fold more macrophages were attracted by Rap flox/flox BMDMs in a transwell macrophage migration assay compared with Mac-Rap KO BMDMs ( Figure 5C ; Online Figure VIIIE ). Consistent with our in vivo study ( Figure 1H ), Raptor deficiency intrinsically reduced macrophage migration to CCL2/monocyte chemoattractant protein 1 (Online Figure VIIIF) . Preincubation with the IL6 antibody substantially reduced macrophage migration in control BMDMs and, to a lesser extent, in Mac-Rap KO macrophages ( Figure 5C and 5D) , consistent with the idea that mmLDL induced IL6, which in turn led to increased chemokine secretion in an mTORC1-dependent fashion.
Discussion
The mTOR inhibitor, rapamycin, has potent immunosuppressive effects and has been widely used to inhibit transplant rejection. Rapamycin blocks cell cycle progression and activation of T lymphocytes and thus inhibits acquired immune responses. 30 Rapamycin has also been found to influence innate immune responses with suppression of chemokine production and variable effects on inflammatory gene expression. 31, 32 In humans and experimental animals, rapamycin suppresses transplant vasculopathy, a specialized form of concentric atherosclerosis with prominent anti-proliferative and anti-migratory effects. 7 There is also evidence that rapamycin decreases atherosclerosis in Apoe −/− mice, 8 despite having adverse effects on very-LDL/ LDL-cholesterol levels. We found prominent induction of mTORC1 activity in macrophages isolated from WTD-fed mice, suggesting an effect of overnutrition to increase mTORC1 activity similar to what occurs in the liver. 33 We then used a cellspecific knockout approach to demonstrate a regulatory role for macrophage mTORC1 in chemokine gene expression and atherogenesis. mTORC1 was found to amplify the effect of IL6/ STAT3 on Ccl2 gene expression, uncovering a novel crosstalk between inflammatory signaling pathways induced by mmLDL and mTORC1 activation produced by overnutrition, in macrophages of atherosclerotic lesions (Online Figure IX) .
Although many cellular factors could potentially contribute to the decreased macrophage content in atherosclerotic lesions of MacRap KO mice, including macrophage autophagy, proliferation, or apoptosis, our studies suggested a predominant role of reduced lesional macrophage chemokine expression and monocyte recruitment into lesions. Studies using Ccr2 −/− BM have suggested a predominant role of CCL2 in promoting monocyte emergence from BM 34 ; however, other studies in which lesional Ccl2/Mcp-1 expression is altered indicate that the gradient of CCL2 between lesion and blood may also play a role in monocyte recruitment into lesions, 35 consistent with our observations. In addition to Ccl2, Ccl3/Mip1α was reduced in MacRap KO macrophages; CCL3 receptors CCR1 and CCR5 may also contribute to the recruitment of classical monocytes into atherosclerotic lesions. 16 Moreover, studies have shown that not only the expression of chemokines by an inflammation site but also by monocytes themselves has a role in the recruitment and migration of monocytes, suggesting autocrine or paracrine effects of chemokines. [36] [37] [38] [39] This may explain the reduced recruitment of carboxy-fluorescein succinimidyl ester-labeled monocytes obtained from MacRap KO donors versus Rap flox/flox controls into the aortas of WTD-fed Ldlr −/− mice. Our studies suggest a dual defect involving both decreased chemokine production by plaque macrophages as well as a cell intrinsic effect of raptor deficiency in migrating monocyte/macrophages, contributing to decreased monocyte/ macrophage migration into plaques.
As reported previously, 40, 41 treatment of macrophages with mmLDL induced the expression of several different chemokine genes, Ccl2, Ccl3, and Ccl7, which have all been implicated in atherogenesis. [42] [43] [44] In this study, we used a mildly oxidized form of LDL to study the mechanisms underlying the suppression of chemokine expression in MacRap KO macrophages. As shown in this study, mmLDL was found to induce Il6 gene expression, and blocking antibodies revealed that the IL6 signaling pathway was required for the induction of chemokines by mmLDL. As expected, IL6 treatment led to phosphorylation of STAT3 on Tyr705. This response was not affected by Raptor deficiency. Rather, a second site, Ser727, was dependent on Raptor deficiency. Previous studies have shown that phosphorylation of Ser727 on STAT3 is required for full transcriptional responses. 26, 27, 45 Although IL6 production induced by mmLDL was intact in Raptor-deficient macrophages, IL6 signaling was decreased because of the reduced phosphorylation of its downstream target STAT3 at Ser727, which resulted in decreased mmLDL-induced chemokine expression. Thus, the impact of macrophage mTORC1 activity was to amplify the effect of mmLDL/IL6 on chemokine gene expression. As shown in Online Figure X , the binding of STAT3 to the chemokine promoter, exemplified by Ccl2, led to the displacement of the transcriptional corepressor BCL6, leading to the induction of chemokine gene expression. These findings are consistent with previous studies demonstrating a key role of BCL6 in macrophage chemokine expression and atherosclerosis 23, 46 and in mediating the effects of mmLDL on chemokine gene expression. 22 Our studies show an important interface between mTORC1 signaling and the mmLDL/IL6/STAT3 signaling axis, mediated by combinatorial STAT3 signaling and leading to an amplification of proatherogenic macrophage chemokine gene expression.
In this study, we used mmLDL and focused on the modulation of IL6 signaling pathway-induced chemokine secretion by mTORC1 signaling. There is increasing evidence for the involvement of IL6 in human atherosclerosis. Inflammatory markers such as C-reactive protein have an independent predictive value for congenital heart disease incidence, and IL6 is a key inflammatory cytokine promoting C-reactive protein production. 47, 48 Recent human genome-wide association studies have shown that single nucleotide polymorphisms in the Il6 receptor gene are associated with coronary artery disease, 49 indicating the relevance of the IL6 signaling pathway in human disease. These data suggest that our studies conducted in a murine atherosclerosis model and with human mmLDL in cell culture could potentially have human relevance and suggest an antiatherogenic role of mTORC1 inhibition in macrophages. mTOR inhibition has potential widespread applications in the treatment of human disease. In addition to transplant rejection, there may be beneficial effects on aging and cancer. 50, 51 However, wholebody mTORC1 inhibition may have adverse effects such as increased LDL levels. 9 Our study suggests a potential role of targeted mTORC1 inhibition in macrophages in the treatment of atherosclerosis. A, Expression levels of chemokines and Tnfα were measured by quantitative reverse transcription polymerase chain reaction (PCR) in wildtype BMDMs 2 h after mmLDL (50 μg/mL) treatment with or without a 1-h rat immunoglobulin G (IgG) against IL6 or isotype control (0.5 μg/ mL) pretreatment and normalized to control (Ctrl); n=3. B, BMDMs from Raptor flox/flox (Rf/f) and Mac-Rap KO (Rf/fCre) mice were treated with IL6 (20 ng/mL) for 2 h. Expression levels of chemokines were measured by quantitative PCR and normalized to expression levels observed without treatment; n=3. C, Macrophage migration assay was performed in which BMDMs from Rf/f and Rf/fCre mice were added to bottom wells and pretreated with mmLDL (50 μg/mL) and rat IgG against IL6 or isotype control for 24 h. The migrated macrophages were quantified by fluorescence spectroscopy; n=3; *P<0.05; 1-way ANOVA; Bonferroni post-test. A.U. indicates arbitary unit; and N.S., not significant.
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